A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

Arterial Ischemic Stroke Clinical Trial

Official title:

A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS) Due to Distal [M2 Segment and Beyond] Arterial Large Vessel Occlusion (LVO) or Perforator Occlusion and Who Are Ineligible for Intravenous Thrombolysis (IVT) or Endovascular Thrombectomy (EVT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04962503
• Other study ID #: CUV801
• Status: Completed
• Phase: Phase 2
• Start date: June 3, 2021
• Est. completion date: February 4, 2022

Study information

• Verified date: March 2023
• Source: Clinuvel Pharmaceuticals Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary study objective is to assess the safety of afamelanotide while the secondary objective is to assess whether the therapy affects the size of the penumbra, by increasing blood flow, restoring oxygen supply to the brain, and reducing the amount of cerebral oedema (fluid) which is seen as a result of the stroke. Positive findings would indicate that the drug is able to support brain tissue-at-risk and provide overall neuroprotection and benefit to stroke patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: February 4, 2022
• Est. primary completion date: February 4, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Male or female subjects with a diagnosis of first AIS due to distal [M2 segment and beyond] occlusion or perforator occlusion

• Perfusion abnormalities observed on Computed Tomography Perfusion (CTP)

• Mild to moderate stroke severity

• Pre-stroke mRS <4

• Written informed consent obtained from patient and/or medical treatment decision maker prior to study-start (upon admission).

Exclusion Criteria:

• Administration of intravenous thrombolytic therapy in distal occlusion as etiology of AIS

• Intervention by endovascular thrombectomy (EVT)

• Known allergy or anaphylaxis to adrenocorticotropic hormone (ACTH) or melanocortins or any of the excipients listed in the Investigator's Brochure

• Any evidence of hepatic (defined as three times standard range) or renal impairment (defined as estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m²)

• Any other medical condition which may interfere with the study protocol

• Female who is pregnant (confirmed by positive serum beta human chorionic gonadotropin (ß-HCG) pregnancy test prior to baseline) or lactating

• Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device) or a lifestyle excluding pregnancy

• Unable to undergo MRI brain evaluation

• Not suitable for trial participation according to judgment of the Principal Investigator (PI)

• Patients starting afamelanotide 24 hours or more from ictus.

Related Conditions & MeSH terms

• Arterial Ischemic Stroke
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Drug:
• Afamelanotide
Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.

Locations

Country	Name	City	State
Australia	The Alfred	Melbourne

Sponsors (1)

Lead Sponsor	Collaborator
Clinuvel Pharmaceuticals Limited

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Volume of Infarct		From Day 0 to Day 3 and Day 0 to Day 9
Secondary	Changes of Neurological Function as Measured by the National Institutional Health Stroke Scale (NIHSS).	0: No stroke symptoms 1-15: Mild to Moderate stroke 16-20: Moderate to severe stroke 21- 42: Severe stroke	From baseline to Day 42
Secondary	Changes of Daily Activities as Measured by the Modified Rankin Scale (mRS)	The mRS indicates the degree of disability or dependence in the daily activities of patients who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms (0) to death (+6).	From baseline to Day 42